Yahoo
NasdaqGS - Delayed Quote USD

Clover Health Investments, Corp. (CLOV)

4.2550 0.0000 (0.00%)
At close: September 4 at 4:00:01 PM EDT
4.2301 -0.0249 (-0.59%)
After hours: September 4 at 7:30:02 PM EDT
Trade CLOV on Coinbase
Chart Range Bar
Loading chart for CLOV

What's happening with CLOV?

47m ago
Powered by Yahoo Scout

Clover Health achieved a $28 million net incomein Q2 2026, a significant turnaround from previous losses, driven by a 48% increasein Medicare Advantage membership. The company raised its full-year revenue guidance to $2.92–3.00 billion, highlighting a strong growth trajectory despite ongoing challenges with medical costs.

Powered by Yahoo Scout
  • Previous Close 4.2550
  • Open 4.2300
  • Bid 4.2400 x 100
  • Ask 4.3500 x 1600
  • Day's Range 4.2200 - 4.2850
  • 52 Week Range 1.5800 - 5.5900
  • Volume 2,057,435
  • Avg. Volume 5,933,650
  • Market Cap (intraday) 2.26B
  • Beta (5Y Monthly) 2.48
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0500
  • Earnings Date (est.) Nov 4, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 5.17

Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals. It also operates Clover Assistant, a software platform for physicians to detect, identify, and manage chronic diseases. The company was founded in 2014 and is based in Wilmington, Delaware.

www.cloverhealth.com

724

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Healthcare Plans

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CLOV
81.06%
S&P 500 (^GSPC)
12.75%

1-Year Return

CLOV
58.18%
S&P 500 (^GSPC)
18.71%

3-Year Return

CLOV
219.92%
S&P 500 (^GSPC)
70.93%

5-Year Return

CLOV
51.87%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 743.17M
Earnings 28M
Profit Margin 3.77%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
200M
400M
600M
-10.0%
-5.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

5.00
5.17 Average
4.2550 Current
5.50 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/6/2026
Analyst UBS
Rating Action Maintains
Rating Neutral
Price Action Raises
Price Target 4.75 -> 5

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -0.74%

  • Return on Assets (ttm)

    -1.77%

  • Return on Equity (ttm)

    -5.10%

  • Revenue (ttm)

    2.48B

  • Net Income Avi to Common (ttm)

    -18.36M

  • Diluted EPS (ttm)

    -0.0500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    243.1M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    69.05M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: